Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

The analysis of FDA-approved next-in-class drugs also found that, among RCTs with head-to-head trials, fewer than 1 in 4 of ...

Relacorilant plus nab-paclitaxel could be a new standard of care for platinum-resistant ovarian cancer, according to Alexander Olawaiye, MD.

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Following the Phase II faceoff between two of Scancell’s lead melanoma immunotherapy candidates, the biotech has selected ...

In March 2024, Lantern dosed two subjects in a Phase Ia/Ib trial of LP-284 for relapsed or refractory non-Hodgkin’s lymphoma ...